Immunomedics, Inc. (NASDAQ:IMMU) – Investment analysts at Jefferies Group lifted their FY2019 earnings estimates for shares of Immunomedics in a report issued on Thursday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings per share of ($0.89) for the year, up from their prior forecast of ($0.91). Jefferies Group has a “Buy” rating and a $11.00 price objective on the stock. Jefferies Group also issued estimates for Immunomedics’ FY2020 earnings at ($0.68) EPS and FY2021 earnings at $0.02 EPS.

ILLEGAL ACTIVITY NOTICE: “FY2019 Earnings Forecast for Immunomedics, Inc. (IMMU) Issued By Jefferies Group” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/fy2019-earnings-forecast-for-immunomedics-inc-immu-issued-by-jefferies-group/1445145.html.

Other analysts have also issued research reports about the company. ValuEngine raised Immunomedics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company began coverage on Immunomedics in a report on Friday, May 26th. They issued an “outperform” rating for the company. Wells Fargo & Company raised Immunomedics from a “market perform” rating to an “outperform” rating in a report on Friday, May 5th. Finally, Zacks Investment Research raised Immunomedics from a “sell” rating to a “buy” rating and set a $9.50 target price for the company in a report on Tuesday, July 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $10.25.

Immunomedics (NASDAQ:IMMU) opened at 9.09 on Monday. The company’s market cap is $996.30 million. The firm has a 50-day moving average price of $7.84 and a 200-day moving average price of $5.80. Immunomedics has a 52 week low of $2.02 and a 52 week high of $9.51.

Several hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY raised its stake in shares of Immunomedics by 3.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 66,049 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 2,384 shares during the last quarter. Creative Planning raised its stake in shares of Immunomedics by 1.7% in the second quarter. Creative Planning now owns 179,130 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 3,065 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Immunomedics by 2.1% in the first quarter. Teachers Advisors LLC now owns 189,537 shares of the biopharmaceutical company’s stock valued at $1,226,000 after buying an additional 3,876 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Immunomedics by 13.8% in the first quarter. HighTower Advisors LLC now owns 58,115 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 7,050 shares during the last quarter. Finally, American International Group Inc. raised its stake in shares of Immunomedics by 17.8% in the first quarter. American International Group Inc. now owns 59,094 shares of the biopharmaceutical company’s stock valued at $382,000 after buying an additional 8,910 shares during the last quarter. 62.06% of the stock is owned by institutional investors.

Immunomedics Company Profile

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Earnings History and Estimates for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.